- Company
- Pantogar's Sales cut in half
- by Mar 8, 2021 06:19am
- OTC hair loss treatment by Merz, Pantogar, was delayed in import, and sales were cut in half. According to the pharmaceutical industry on the 4th, import of Pantogar has been temporarily suspended from the middle of last year due to changes in overseas manufacturing sites. It was sold out as Pantogar's domestic distribution was stopped.
- Policy
- Amivantamab designated as a rare drug
- by Lee, Tak-Sun Mar 8, 2021 06:19am
- Janssen's Amivantamab, which is promoting joint development with Yuhan's non-small cell lung cancer treatment Leclaza, has been newly designated as an orphan drug. The MFDS announced that it will newly designate five drugs, including Amivantamab, as orphan drugs, and announce additional target diseases for three drugs, including 5-Aminolevuli
- Company
- Hepatitis C treatment Vosevi was refocused
- by Eo, Yun-Ho Mar 5, 2021 06:26am
- Gilead is aiming to enter the market for hepatitis C treatment Vosevi, which has failed to designate an orphan drug in Korea. According to related industries, Gilead Science Korea is in the process of marketing approval of the three-drug combination Vosevi (Sofosbuvir + Velpatasvir + Voxilaprevir) along with the hepatitis C combination dr
- Opinion
- [Reporter’s Eye] Be aware of fake news trampling the hope
- by An, Kyung-Jin Mar 5, 2021 06:26am
- Recently, the South Korean media industry is intensely disputing over a bill imposing punitive damages. Democratic Party Lawmaker Noh Woong-rae issued a legislative notice on a bill to include general media and portal websites as subjects for the punitive damages, which awards compensation valuing maximum of triple the damages to a prevailin
- Policy
- 1 free dose of rare cancer treatment Lutathera
- by Lee, Tak-Sun Mar 5, 2021 06:25am
- Apparently, South Korea’s Ministry of Food and Drug Safety (MFDS) is to lessen the patient’s financial burden through a patient aid program for a rare cancer treatment Lutathera until it gets officially listed for reimbursement. The government program would grant a free dose of the treatment. MFDS announced the Lutathera patient aid p
- Company
- Sales of Tagrisso tripled in four years
- by An, Kyung-Jin Mar 5, 2021 06:25am
- The market for targeted anticancer drugs for EGFR, which is prescribed to patients with non-small cell lung cancer with specific mutation findings, set a record for sales last year. The benefit of Tagrisso, a third-generation drug that is effective in the treatment of resistance to existing drugs, has been listed. According to IQVIA on the 2n
- Policy
- Jardiance generics win approvals one after another
- by Lee, Jeong-Hwan Mar 4, 2021 06:10am
- A series of generics of Boehringer Ingelheim Korea’s antidiabetic sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin) seem to be receiving the market authorization one after another. On Mar. 3, South Korea’s Ministry of Food and Drug Safety (MFDS) authorized Korea Prime Pharm’s Empazin 10 mg and 20 mg tablets.
- Company
- Roche has applied for insurance benefits of Polivy
- by Eo, Yun-Ho Mar 4, 2021 06:10am
- According to related industries, Roche Korea has submitted an application for Polivy (Polatuzumab), an antibody-drug conjugate (ADC) that is used in combination with conventional BR therapy (Bendamustine+Rituximab) for the treatment of Diffuse Large B-Cell Lymphoma and DLBCL. DLBCL, which accounts for the highest proportion of Non-Hodgkin ly
- Company
- Samsung Bioepis enters phase 1 of Stelara
- by Lee, Seok-Jun Mar 4, 2021 06:10am
- Samsung Bioepis has begun phase 1 clinical trial of the 10th biosimilar pipeline SB17. SB17 is a biosimilar for Stelara (Ustekinumab). Samsung Bioepis launched Phase 1 in February to confirm the pharmacokinetics, safety, and immunogenicity of SB17 for 201 healthy volunteers in France. Stelara is a treatment for autoimmune diseases such
- Policy
- Single-dose Janssen COVID-19 vaccine requests authorization
- by Lee, Tak-Sun Mar 4, 2021 06:10am
- Janssen’s COVID-19 vaccine to be introduced to South Korea in the second quarter has officially requested for authorization to the Ministry of Food and Drug Safety (MFDS). Following AstraZeneca and Pfizer, the multinational company would be a third company to apply for the authorization on COVID-19 vaccine in the country. On Feb. 27, MF
